CN Patent

CN116963734A — 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途

Assigned to Mirati Therapeutics Inc · Expires 2023-10-27 · 3y expired

What this patent protects

本发明涉及多重酪胺酸激酶抑制剂的苹果酸盐。特别地，本发明涉及多重酪胺酸激酶抑制剂(S)‑2‑羟基琥珀酸N‑(3‑氟‑4‑((2‑(5‑(((2‑甲氧基乙基)氨基)甲基)吡啶‑2‑基)噻吩并[3,2‑b]吡啶‑7‑基)氧基)苯基)‑N‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺(1:1)的苹果酸盐的结晶形式、包含该结晶形式的药物组合物、用于制备该结晶形式的方法和该结晶形式的使用方法。

USPTO Abstract

本发明涉及多重酪胺酸激酶抑制剂的苹果酸盐。特别地，本发明涉及多重酪胺酸激酶抑制剂(S)‑2‑羟基琥珀酸N‑(3‑氟‑4‑((2‑(5‑(((2‑甲氧基乙基)氨基)甲基)吡啶‑2‑基)噻吩并[3,2‑b]吡啶‑7‑基)氧基)苯基)‑N‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺(1:1)的苹果酸盐的结晶形式、包含该结晶形式的药物组合物、用于制备该结晶形式的方法和该结晶形式的使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116963734A
Jurisdiction
CN
Classification
—
Expires
2023-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.